A related comment notes that cerebellar ataxias encompass a multitude of different, rare genetic entities. Therapeutic trials are limited by small patient numbers, and therefore risk being underpowered. The author discusses whether it is appropriate to mix different forms of ataxias in a therapeutic trial and conclude that ‘the next step is to determine exactly which subgroups of patients with cerebellar ataxia respond to riluzole and could therefore benefit from treatment.’